Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM200
- Development stage
- Preclinical
- Lead developer
- Vision Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VM200 is an oral small molecule drug candidate developed by Vision Medicines, licensed from Case Western Reserve University. It is intended for the treatment of Stargardt disease, an orphan retinal disease that leads to legal blindness. The drug's mechanism of action involves trapping a toxic vitamin A byproduct, which in turn reduces retinal damage. Its development is supported by funding from the Foundation Fighting Blindness, aiming to advance it from preclinical stages through clinical proof-of-concept.
02
Targets
ATR (ATR serine/threonine kinase)A2E
Beyond the preview
Go deeper on VM200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM200.